Thus, inhibition of fructose metabolism is considered an attractive therapeutic approach for NAFLD/NASH (43), and a recent study provides preclinical evidence supporting KHK inhibition to improve NAFLD/NASH (44). The gene discussed is KHK; the disease is metabolic dysfunction-associated steatohepatitis.